Several initiatives are encouraging pharmaceutical companies to bolster development of drugs for rare and neglected medical conditions. The NIH is set to launch in the fall a scientific center to transform genetic discoveries into therapies, while the International Rare Diseases Research Consortium is aiming for at least 200 more orphan drugs by 2020. Furthermore, senators introduced a bipartisan bill that would give drugmakers an incentive to developing treatments for children with rare diseases.

Full Story:

Related Summaries